<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>olanzapine</title><link>http://www.unboundmedicine.com/medline/ebm/research/olanzapine</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19890258/full_citation/Early_Response_to_Antipsychotic_Drug_Therapy_as_a_Clinical_Marker_of_Subsequent_Response_in_the_Treatment_of_Schizophrenia_</link><description>Kinon BJ, Chen L, Ascher-Svanum H, et al. <br/><span class="title">Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. [JOURNAL ARTICLE]</span><br/><span class="source" title="Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology">Neuropsychopharmacology 2009 Nov 4.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19890258/abstract/Early_Response_to_Antipsychotic_Drug_Therapy_as_a_Clinical_Marker_of_Subsequent_Response_in_the_Treatment_of_Schizophrenia_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19890258/full_citation/Early_Response_to_Antipsychotic_Drug_Therapy_as_a_Clinical_Marker_of_Subsequent_Response_in_the_Treatment_of_Schizophrenia_">Full Citation</a></description></item><item><title>Mifepristone treatment of olanzapine-induced weight gain in healthy men.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19888560/full_citation/Mifepristone_treatment_of_olanzapine_induced_weight_gain_in_healthy_men_</link><description>Gross C, Blasey CM, Roe RL, et al. <br/><span class="title">Mifepristone treatment of olanzapine-induced weight gain in healthy men. [JOURNAL ARTICLE]</span><br/><span class="source" title="Advances in therapy">Adv Ther 2009 Nov 4.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19888560/abstract/Mifepristone_treatment_of_olanzapine_induced_weight_gain_in_healthy_men_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19888560/full_citation/Mifepristone_treatment_of_olanzapine_induced_weight_gain_in_healthy_men_">Full Citation</a></description></item><item><title>Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19877981/full_citation/Lack_of_effect_of_stimulant_combination_with_second_generation_antipsychotics_on_weight_gain_metabolic_changes_prolactin_levels_and_sedation_in_youth_with_clinically_relevant_aggression_or_oppositionality_</link><description>Penzner JB, Dudas M, Saito E, et al. <br/><span class="title">Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="Journal of child and adolescent psychopharmacology">J Child Adolesc Psychopharmacol 2009 Oct; 19(5):563-73.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19877981/abstract/Lack_of_effect_of_stimulant_combination_with_second_generation_antipsychotics_on_weight_gain_metabolic_changes_prolactin_levels_and_sedation_in_youth_with_clinically_relevant_aggression_or_oppositionality_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19877981/full_citation/Lack_of_effect_of_stimulant_combination_with_second_generation_antipsychotics_on_weight_gain_metabolic_changes_prolactin_levels_and_sedation_in_youth_with_clinically_relevant_aggression_or_oppositionality_">Full Citation</a></description></item><item><title>Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19877978/full_citation/Comparison_of_open_label_8_week_trials_of_olanzapine_monotherapy_and_topiramate_augmentation_of_olanzapine_for_the_treatment_of_pediatric_bipolar_disorder_</link><description>Wozniak J, Mick E, Waxmonsky J, et al. <br/><span class="title">Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. [Journal Article, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="Journal of child and adolescent psychopharmacology">J Child Adolesc Psychopharmacol 2009 Oct; 19(5):539-45.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19877978/abstract/Comparison_of_open_label_8_week_trials_of_olanzapine_monotherapy_and_topiramate_augmentation_of_olanzapine_for_the_treatment_of_pediatric_bipolar_disorder_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19877978/full_citation/Comparison_of_open_label_8_week_trials_of_olanzapine_monotherapy_and_topiramate_augmentation_of_olanzapine_for_the_treatment_of_pediatric_bipolar_disorder_">Full Citation</a></description></item><item><title>Effect of Valproate on Olanzapine Plasma Concentrations in Patients With Bipolar or Schizoaffective Disorder.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19865002/full_citation/Effect_of_Valproate_on_Olanzapine_Plasma_Concentrations_in_Patients_With_Bipolar_or_Schizoaffective_Disorder_</link><description>Spina E, Dʼarrigo C, Santoro V, et al. <br/><span class="title">Effect of Valproate on Olanzapine Plasma Concentrations in Patients With Bipolar or Schizoaffective Disorder. [JOURNAL ARTICLE]</span><br/><span class="source" title="Therapeutic drug monitoring">Ther Drug Monit 2009 Oct 27.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19865002/abstract/Effect_of_Valproate_on_Olanzapine_Plasma_Concentrations_in_Patients_With_Bipolar_or_Schizoaffective_Disorder_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19865002/full_citation/Effect_of_Valproate_on_Olanzapine_Plasma_Concentrations_in_Patients_With_Bipolar_or_Schizoaffective_Disorder_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19865002/Effect_of_Valproate_on_Olanzapine_Plasma_Concentrations_in_Patients_With_Bipolar_or_Schizoaffective_Disorder_">Find Related Articles</a> </description></item><item><title>Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs with pimavanserin (ACP 103), a 5-hydroxytryptamine2A receptor inverse agonist.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19864614/full_citation/Attenuation_of_phencyclidine_induced_object_recognition_deficits_by_the_combination_of_atypical_antipsychotic_drugs_with_pimavanserin__ACP_103__a_5_hydroxytryptamine2A_receptor_inverse_agonist_</link><description>Snigdha S, Horiguchi M, Li Z, et al. <br/><span class="title">Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs with pimavanserin (ACP 103), a 5-hydroxytryptamine2A receptor inverse agonist. [JOURNAL ARTICLE]</span><br/><span class="source" title="The Journal of pharmacology and experimental therapeutics">J Pharmacol Exp Ther 2009 Oct 28.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19864614/abstract/Attenuation_of_phencyclidine_induced_object_recognition_deficits_by_the_combination_of_atypical_antipsychotic_drugs_with_pimavanserin__ACP_103__a_5_hydroxytryptamine2A_receptor_inverse_agonist_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19864614/full_citation/Attenuation_of_phencyclidine_induced_object_recognition_deficits_by_the_combination_of_atypical_antipsychotic_drugs_with_pimavanserin__ACP_103__a_5_hydroxytryptamine2A_receptor_inverse_agonist_">Full Citation</a> | <a href="http://jpet.aspetjournals.org/cgi/pmidlookup%3fview=long%26amp;pmid=19864614">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19864614/Attenuation_of_phencyclidine_induced_object_recognition_deficits_by_the_combination_of_atypical_antipsychotic_drugs_with_pimavanserin__ACP_103__a_5_hydroxytryptamine2A_receptor_inverse_agonist_">Find Related Articles</a> </description></item><item><title>Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19864114/full_citation/Impact_of_antipsychotic_medication_on_family_burden_in_schizophrenia:_Longitudinal_results_of_CATIE_trial_</link><description>Perlick DA, Rosenheck RA, Kaczynski R, et al. <br/><span class="title">Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial. [JOURNAL ARTICLE]</span><br/><span class="source" title="Schizophrenia research">Schizophr Res 2009 Oct 27.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19864114/abstract/Impact_of_antipsychotic_medication_on_family_burden_in_schizophrenia:_Longitudinal_results_of_CATIE_trial_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19864114/full_citation/Impact_of_antipsychotic_medication_on_family_burden_in_schizophrenia:_Longitudinal_results_of_CATIE_trial_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19864114/Impact_of_antipsychotic_medication_on_family_burden_in_schizophrenia:_Longitudinal_results_of_CATIE_trial_">Find Related Articles</a> </description></item><item><title>Early exposure to haloperidol or olanzapine induces long-term alterations of dendritic form.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19862684/full_citation/Early_exposure_to_haloperidol_or_olanzapine_induces_long_term_alterations_of_dendritic_form_</link><description>Frost DO, Page SC, Carroll C, et al. <br/><span class="title">Early exposure to haloperidol or olanzapine induces long-term alterations of dendritic form. [JOURNAL ARTICLE]</span><br/><span class="source" title="Synapse (New York, N.Y.)">Synapse 2009 Oct 26; 64(3):191-199.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19862684/abstract/Early_exposure_to_haloperidol_or_olanzapine_induces_long_term_alterations_of_dendritic_form_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19862684/full_citation/Early_exposure_to_haloperidol_or_olanzapine_induces_long_term_alterations_of_dendritic_form_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19862684/Early_exposure_to_haloperidol_or_olanzapine_induces_long_term_alterations_of_dendritic_form_">Find Related Articles</a> </description></item><item><title>Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19861668/full_citation/Cardiometabolic_risk_of_second_generation_antipsychotic_medications_during_first_time_use_in_children_and_adolescents_</link><description>Correll CU, Manu P, Olshanskiy V, et al. <br/><span class="title">Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]</span><br/><span class="source" title="JAMA : the journal of the American Medical Association">JAMA 2009 Oct 28; 302(16):1765-73.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19861668/abstract/Cardiometabolic_risk_of_second_generation_antipsychotic_medications_during_first_time_use_in_children_and_adolescents_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19861668/full_citation/Cardiometabolic_risk_of_second_generation_antipsychotic_medications_during_first_time_use_in_children_and_adolescents_">Full Citation</a> | <a href="http://jama.ama-assn.org/cgi/pmidlookup%3fview=long%26amp;pmid=19861668">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19861668/Cardiometabolic_risk_of_second_generation_antipsychotic_medications_during_first_time_use_in_children_and_adolescents_">Find Related Articles</a> </description></item><item><title>Delusions of parasitosis.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19857422/full_citation/Delusions_of_parasitosis_</link><description>Edlich RF, Cross CL, Wack CA, et al. <br/><span class="title">Delusions of parasitosis. [Journal Article]</span><br/><span class="source" title="The American journal of emergency medicine">Am J Emerg Med 2009 Oct; 27(8):997-9.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19857422/abstract/Delusions_of_parasitosis_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19857422/full_citation/Delusions_of_parasitosis_">Full Citation</a> | <a href="http://linkinghub.elsevier.com/retrieve/pii/S0735-6757(08)00535-4">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19857422/Delusions_of_parasitosis_">Find Related Articles</a> </description></item></channel></rss>